AbbVie Invests US$195 Million to Expand API Manufacturing in USA
Introduction:
AbbVie plans to invest US$195 million to expand active pharmaceutical ingredient (API) manufacturing at its North Chicago facility in the United States.
Features:
A new facility is planned in North Chicago for the production of active pharmaceutical ingredients (APIs) using chemical synthesis.
The site will supply components for medicines in neuroscience, immunology, and oncology.
Construction is scheduled to begin in autumn 2025, with operations expected to start in 2027.
The facility will form part of the wider U.S. pharmaceutical manufacturing network. It is intended to strengthen domestic production of APIs and reduce reliance on overseas supply.
The site will expand chemical synthesis capabilities within the United States. Production will cover APIs for existing treatments as well as potential future medicines.
The development supports national efforts to secure the pharmaceutical supply chain. Infrastructure will be established to enable large-scale, long-term production of APIs.
The project is expected to provide additional manufacturing capacity for therapies across multiple therapeutic areas.
Specifications:
| Name | AbbVie |
| Type | New Construction |
| Budget | US$195 million |
| Year | 2027 |
